GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

IN MARIETTA, L Hundreds of millions of dollars and hundreds of new jobs are coming to Lancaster County.Vaccine manufacturer GSK announced Thursday it will invest $800 million to expand its ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

GSK has shifted towards a global marketing model ... “It then becomes our job to partner with the global teams to operationalise the leader’s vision and how it comes to life.

A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

GSK plans to invest $800 million in its East ... that would add research and manufacturing capabilities along with 200 jobs. The British multinational pharmaceutical and biotechnology company ...

creating around 200 new jobs. The centrepiece of the new investment is a multi-purpose facility capable of manufacturing sterile liquid vaccines and medicines, for which GSK says there is "ever ...

GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group. “​​At this time, we believe there are other areas ...

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...